ICMR seeks collaboration for malaria vaccine production through tech transfer

Indian Council of Medical Analysis (ICMR), Delhi, has invited Expression of Curiosity (EoI) from eligible organisations, corporations and producers for endeavor ‘Switch of Expertise’ for commercialisation of “a recombinant chimeric multi-stage malaria vaccine (AdFalciVax) towards Plasmodium falciparum” helpful in stopping Plasmodium falciparum an infection in people and minimizing its group transmission. The aim is to facilitate the commercialisation of this vaccine to stop and decrease malaria transmission, and the EoI is open till August 17.

The Council famous that it could present technical assist by means of its workforce of skilled scientists in research planning, product growth, growth of research protocol, outcomes/information evaluation, end result evaluation, security and efficacy evaluation, product enchancment, and so on., if deemed match upon mutual understanding between ICMR and the collaborative firm.

Moreover, whereas the Council could have no monetary implications except in any other case specified, its Institutes would supply assist and facilitation to conduct the analysis and growth (R&D)/scientific research of latest expertise/product in India by means of its associates/institutes, in collaboration with the corporate/establishments. It might additionally present technical assist in growth of expertise/product and also will facilitate the validation, if required.

“ICMR-Regional Medical Analysis Centre, Bhubaneswar (ICMR-RMRCBB) is without doubt one of the 4 constituent institutes that has led the event of the expertise and has technical-know-how of the method to supply this recombinant chimeric multi-stage malaria vaccine in Lactococcus lactis. The pre-clinical validation of this expertise was performed in collaboration with ICMR-Nationwide Institute of Malaria Analysis (ICMR-NIMR), one other constituent institute of ICMR, and Nationwide Institute of Immunology (NII), New Delhi, an autonomous analysis institute of the Division of Biotechnology,” it added.